(NASDAQ: CLRB) Cellectar Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Cellectar Biosciences's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CLRB's revenue for 2024 to be $112,589,180, with the lowest CLRB revenue forecast at $112,589,180, and the highest CLRB revenue forecast at $112,589,180. On average, 2 Wall Street analysts forecast CLRB's revenue for 2025 to be $1,760,133,426, with the lowest CLRB revenue forecast at $654,888,353, and the highest CLRB revenue forecast at $2,865,378,498.
In 2026, CLRB is forecast to generate $3,449,616,334 in revenue, with the lowest revenue forecast at $1,971,117,161 and the highest revenue forecast at $4,928,115,508.